Background: Serasis® (Serag-Wiessner KG, Naila, Germany) is a light-weight mid-urethral sling for treating stress urinary incontinence (SUI). Its insertion is considered less traumatic than other mid-urethral slings.
Objectives: To define postoperative outcomes following Serasis implantation. To compare the efficacy and complication rates of the implant to those of other common techniques.
Methods: Our retrospective study evaluated patients who underwent Serasis mid-urethral sling surgery for SUI. Data were collected from medical records prior to and at the time of surgery and by telephonic interview for postoperative pain and complications. Follow-up of patients was performed for up to one year postoperatively. Patients rated pain or discomfort according to the Visual Analogue Scale (VAS). The primary outcome was the development of early postoperative pain during the first month after surgery. Secondary outcomes were relief of SUI symptoms, groin pain or discomfort, and other postoperative complications up to 12 months after surgery.
Results: The study cohort included 50 consecutive patients aged 31 to 68 years. All patients underwent Serasis implantation procedures by a single surgeon and completed interviews. In total, 35 patients underwent concomitant anterior colporrhaphy. In the immediate postoperative period and at one month after the procedure, complaints were mild. No complaints were recorded during the 12-month follow-up period. Overall, 90% and 92% of the patients were free of SUI symptoms at one month and 12 months after surgery, respectively.
Conclusions: Serasis mid-urethral sling is safe, effective, and associated with mild postoperative pain and a low incidence of complications.
Download full-text PDF |
Source |
---|
Int Urol Nephrol
December 2024
Yokosuka Urogynecology and Urology Clinic, Ootaki 2-6, Yokosuka, Kanagawa, 238-0008, Japan.
Purpose: To evaluate two primary outcomes in elite female athletes (EFAs) with severe stress urinary incontinence (SUI) 24 months post-intervention: return to elite-level competition and improvement in SUI symptoms. Clustering analysis was conducted to identify subgroups within the patient population and explore treatment efficacy.
Methods: A retrospective analysis was performed on 183 EFAs with severe SUI who underwent treatments including pelvic floor muscle training (PFMT), vaginal and urethral erbium laser (Fotona Laser), and mid-urethral sling (MUS) surgery.
Int Urogynecol J
December 2024
Clinique Sainte Barbe, Groupe Hospitalier Saint Vincent, Strasbourg, France.
Introduction And Hypothesis: Various treatment options are currently available for the management of stress urinary incontinence (SUI). This study was aimed at determining the effectiveness and safety profile of Bulkamid, and identify predictive factors of clinical success.
Methods: This retrospective study conducted in two French urogynecology university centers between September 2019 and December 2023 included all patients with urinary incontinence who received Bulkamid.
Cureus
November 2024
Obstetrics and Gynecology, Tata Central Hospital, Dhanbad, IND.
Stress urinary incontinence (SUI) is a common disorder in females, which significantly affects the quality of life in females. There are many consensus that describe the safety of childbearing after surgery for SUI, but still, a large proportion of surgeons worldwide recommend that women should wait to complete childbearing before pursuing surgical treatment for SUI. There is also some opinion that if patients conceive after surgical treatment for SUI, women should be delivered by cesarean section.
View Article and Find Full Text PDFArch Esp Urol
November 2024
Gynecology Department, Ningbo No. 2 Hospital, 315000 Ningbo, Zhejiang, China.
Int J Womens Health
November 2024
Department of Gynecology, Minda Hospital of Hubei Minzu University, Enshi, Enshi Tujia and Miao Autonomous Prefecture, Hubei, People's Republic of China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!